About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/25/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/25/2020.
Our Science
  • Pipeline Molecules

    We invest significant resources into creating disease-altering therapies for cancers. Hundreds of clinical studies around the world use our innovative treatment.

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

    Filter by:

    Flip

    Phase 1

    AG-270

    MAT2A Inhibitor

    Flip

    Azacitidine

    ( DNA Methyltransferase Inhibitor )

    Learn More View clinical trials
    with this compound
    Phase

    Azacitidine

    DNA Methyltransferase Inhibitor

    Azacitidine is a cytidine nucleoside analogue that is incorporated into newly synthesized DNA as well as RNA.

    Learn More

    Flip

    bb21217

    ( Anti-BCMA CAR T Cells )

    View clinical trials
    with this compound
    Phase 2

    bb21217

    Anti-BCMA CAR T Cells

    Flip

    CC-486

    ( DNA Methyltransferase Inhibitor )

    Learn More View clinical trials
    with this compound
    Phase 1, Phase 2, Phase 3

    CC-486

    DNA Methyltransferase Inhibitor

    The epigenetic modifier CC-486 (an oral formulation of azacitidine) is a cytidine nucleoside analogue.

    Learn More

    Flip

    Phase 2

    CC-90001

    JNK Inhibitor

    Flip

    CC-90009

    ( Cereblon/E3 Ligase Modulator )

    View clinical trials
    with this compound
    Phase 1

    CC-90009

    Cereblon/E3 Ligase Modulator

    Flip

    Phase 1

    CC-90010

    BET Inhibitor

    Flip

    CC-90011

    ( LSD1 Inhibitor )

    View clinical trials
    with this compound
    Phase 1

    CC-90011

    LSD1 Inhibitor

    Flip

    CC-92480

    ( Cereblon/E3 Ligase Modulator )

    View clinical trials
    with this compound
    Phase 1

    CC-92480

    Cereblon/E3 Ligase Modulator

    Flip

    CC-93269

    ( Anti-BCMA T-Cell Engager )

    Learn More View clinical trials
    with this compound
    Phase 1

    CC-93269

    Anti-BCMA T-Cell Engager

    CC-93269 is an investigational, humanized IgG1-based 2+1 T-cell engager (TCE) designed to bind to B-cell maturation antigen (BCMA).

    Learn More

    Flip

    Cendakimab

    ( Anti-IL13 Antibody )

    View clinical trials
    with this compound
    Phase 2

    Cendakimab

    Anti-IL13 Antibody

    Flip

    CC-95251

    ( Anti-SIRPα Antibody )

    View clinical trials
    with this compound
    Phase 1

    CC-95251

    Anti-SIRPα Antibody

    Flip

    Phase 1

    CC-95775

    BET Inhibitor

    Flip

    CC-99282

    ( Cereblon/E3 Ligase Modulator )

    View clinical trials
    with this compound
    Phase 1

    CC-99282

    Cereblon/E3 Ligase Modulator

    Flip

    CC-99712

    ( Anti-BCMA Antibody Drug Conjugate )

    View clinical trials
    with this compound
    Phase 1

    CC-99712

    Anti-BCMA Antibody Drug Conjugate

    Flip

    Phase 2, Phase 3

    Enasidenib

    IDH2 Inhibitor

    Enasidenib is an oral, reversible, selective inhibitor of mutated isocitrate dehydrogenase (IDH) 2.

    Learn More

    Flip

    Phase 3

    Fedratinib

    JAK2 Inhibitor

    Fedratinib is an investigational, selective, small-molecule, ATP-competitive inhibitor of Janus kinase 2 (JAK2).

    Learn More

    Flip

    GEM333

    ( CD3XCD33 Bispecific Antibody )

    View clinical trials
    with this compound
    Phase 1

    GEM333

    CD3XCD33 Bispecific Antibody

    Flip

    GEM3PSCA

    ( CD3XPSCA Bispecific Antibody )

    View clinical trials
    with this compound
    Phase 1

    GEM3PSCA

    CD3XPSCA Bispecific Antibody

    Flip

    Iberdomide (CC-220)

    ( CELMoD® agent )

    Learn More View clinical trials
    with this compound
    Phase 1, Phase 2

    Iberdomide (CC-220)

    CELMoD® agent

    Iberdomide is a CELMoD agent.

    Learn More

    Flip

    Idecabtagene vicleucel (ide-cel; bb2121)

    ( Anti-BCMA CAR T Cells )

    Learn More View clinical trials
    with this compound
    Phase 2, Phase 3

    Idecabtagene vicleucel (ide-cel; bb2121)

    Anti-BCMA CAR T Cells

    Idecabtagene vicleucel (Ide-cel; bb2121) is an investigational chimeric antigen receptor (CAR) T cell therapy targeting B-cell maturation agent.

    Learn More

    Flip

    Orvacabtagene autoleucel (orva-cel; JCARH125)

    ( Anti-BCMA CAR T Cells )

    View clinical trials
    with this compound
    Phase 1

    Orvacabtagene autoleucel (orva-cel; JCARH125)

    Anti-BCMA CAR T Cells

    Flip

    Phase 3, Phase Post Approval Research

    Lenalidomide

    IMiD® Agent

    Lenalidomide is an oral, small-molecule immunomodulatory agent.

    Learn More

    Flip

    Lisocabtagene maraleucel (liso-cel; JCAR017)

    ( Anti-CD19 CAR T Cells )

    Learn More View clinical trials
    with this compound
    Phase 2, Phase 3

    Lisocabtagene maraleucel (liso-cel; JCAR017)

    Anti-CD19 CAR T Cells

    Lisocabtagene maraleucel (liso-cel;JCAR017) is an investigational chimeric antigen receptor (CAR) T cell therapy designed to target CD19.

    Learn More
    Phase 2, Phase 3

    Luspatercept-aamt

    Luspatercept-aamt (ACE-536) is a soluble fusion protein hypothesized to act as an erythroid maturation agent.

    Learn More

    Flip

    Marizomib

    ( Proteasome Inhibitor )

    Learn More View clinical trials
    with this compound
    Phase 3

    Marizomib

    Proteasome Inhibitor

    Marizomib is a proteasome inhibitor derived from a novel marine-obligate actinomycete.

    Learn More

    Flip

    Phase 1

    Motolimod

    TLR8 Agonist

    Flip

    nab-Paclitaxel

    ( Albumin-Bound Microtubule Inhibitor )

    Learn More View clinical trials
    with this compound
    Phase 3, Phase Post Approval Research

    nab-Paclitaxel

    Albumin-Bound Microtubule Inhibitor

    nab-Paclitaxel is a taxane that uses albumin to deliver paclitaxel.

    Learn More
    Phase 3

    Ozanimod

    S1P

    Ozanimod is an oral, sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5).

     

    Learn More

    Flip

    Phase Post Approval Research

    Pomalidomide

    IMiD® Agent

    Pomalidomide is an oral immunomodulatory agent.

    Learn More

    Flip

    Romidepsin

    ( Histone Deacetylase Inhibitor )

    Learn More View clinical trials
    with this compound
    Phase 3, Phase Post Approval Research

    Romidepsin

    Histone Deacetylase Inhibitor

    The epigenetic modifier romidepsin is a potent class 1 selective histone deacetylase inhibitor.

    Learn More

    Flip

    Thalidomide
    Phase Post Approval Research

    Thalidomide